Iridium Network invests in RayCare to become its main oncology information system


STOCKHOLM, October 29, 2021 / PRNewswire / – Iridium Network has made a significant contribution to the development of RayCare and in February 2018 it became the first hospital in the world to clinically use RayCare, just two months after the system was released. Currently, RayStation® * and RayCare are both clinically implemented in the treatment of all stereotaxic body radiation therapy (SBRT) as well as radiosurgery (SRS) treatments. Now, the goal is to further streamline the workflow to eventually be able to manage all clinical activities, for all types of cancer and in all of their clinics, with RayCare. Achieving this level of standardization and automation represents an important milestone in the RaySearch-Iridium Network partnership and in healthcare for the greater Antwerp Region.

RaySearch and Iridium Network also have a close collaboration on machine learning, creation and validation of segmentation and planning models. This project has been very successful and will be further extended in the coming years to an increased level of automation with machine learning for the majority of processing sites.

Teacher. Dr. Dirk Verellen, Iridium Network, says: “The clinical workflow in radiation oncology is becoming increasingly complex with the introduction of personalized and adaptive treatments. Standardization and automation are key elements in ensuring patient safety and quality assurance in this constantly changing environment. RaySearch is the ideal partner to coordinate and monitor our clinical care pathways across the network and provide access to state-of-the-art radiation oncology for every patient in the greater region of Antwerp. “

Teacher. Dr. Piet Dirix, Iridium Network, said: “Cancer cases are expected to increase by 2030, with an expected increase of at least 30% in new diagnoses globally. their disease, we are preparing to treat many more patients without necessarily having more resources. Our clinical experience with RayStation and RayCare has taught us that we can treat our patients safer, more accurately and more efficiently with these systems working in tandem. , we believe we can treat our growing number of patients with our current resources thanks to these smart software innovations. “

Johan Löf, Founder and CEO of RaySearch, said: “This long-term commitment of Iridium Network demonstrates its confidence in RayCare as an innovative oncology information system contributing to safe and effective cancer care. The clinical expertise and high commitment of Iridium Network have been instrumental in the development of RayCare, and we look forward to reaching the milestone of connecting RayCare to Varian TrueBeam® ** linacs at Iridium. “

About the Iridium network

Iridium is a highly specialized radio-oncology network for the 3 hospital networks (MIRA, HELIX and GZA / ZNA) of the greater region of Antwerp, representing 18 hospital sites. Founded in 2006, Iridium Network is today the largest radiotherapy network in Belgium and a leading center of expertise of international renown. By the end of 2021, the milestone of 6,000 annual treatments will be exceeded. The head office is located on the campus of the GZA Sint-Augustinus hospitals in Wilrijk.

About RaySearch

RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions to improve cancer treatment. RaySearch markets the RayStation® Treatment Planning System (TPS) and the RayCare® Oncology Information System (OIS). The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®. RayIntelligence is an oncology analysis system (OAS) that enables cancer clinics to collect, structure and analyze data. RayCommand®, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.

RaySearch software is used by over 2,600 clinics in over 65 countries. The company was founded in 2000 as a spin-off of the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003.

About RayStation

RayStation® is a flexible and innovative treatment planning system chosen by many of the world’s leading cancer centers. It combines unique features such as unmatched adaptive therapy capabilities, multi-criteria optimization, advanced algorithms for treatment plan optimization for HDR brachytherapy and external beam therapy with photons, electrons and protons, as well as helium and carbon ions. RayStation supports a wide range of processing machines, providing a control center for all processing planning needs and ensuring that centers get more value from existing equipment. RayStation also integrates seamlessly with RayCare. By aligning treatment planning, we are enabling better care of cancer patients around the world.

About RayCare

The RayCare® Oncology Information System (OIS) is designed to support the many complex logistical challenges facing today’s oncology clinics. RayCare is tightly integrated with RayStation® and provides seamless access to all of the powerful planning tools of RayStation and RayCommand®. The system effectively coordinates radiation therapy activities and provides advanced functionality for clinical workflow automation and adaptive radiation therapy. RayCare responds to clinics’ demand for a more user-friendly, workflow-oriented information system that can support the future of cancer care.

* Subject to regulatory approval in certain markets.
** The Varian and TrueBeam brands are registered trademarks of Varian Medical Systems Inc.

More information about RaySearch is available at


For more information please contact:

Johan Löf, Founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8-510 530 00
[email protected]

Pierre Thysell, CFO, RaySearch Laboratories AB (published)
Telephone: +46 (0) 70 661 05 59
[email protected]

This information was brought to you by Cision,c3443541

The following files are available for download:

SOURCE RaySearch Laboratories


Comments are closed.